Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BFRI 
Biofrontera Inc (BFRI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: BFRI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.76% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.44M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 2 | Beta 0.56 | 52 Weeks Range 0.54 - 1.25 | Updated Date 12/3/2025 |
52 Weeks Range 0.54 - 1.25 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-13 | When - | Estimate -0.56 | Actual -0.5687 |
Profitability
Profit Margin -47.28% | Operating Margin (TTM) -89.84% |
Management Effectiveness
Return on Assets (TTM) -64.91% | Return on Equity (TTM) -1191.73% |
Valuation
Trailing PE - | Forward PE 13 | Enterprise Value 10957405 | Price to Sales(TTM) 0.25 |
Enterprise Value 10957405 | Price to Sales(TTM) 0.25 | ||
Enterprise Value to Revenue 0.29 | Enterprise Value to EBITDA -0.79 | Shares Outstanding 11648323 | Shares Floating 9105145 |
Shares Outstanding 11648323 | Shares Floating 9105145 | ||
Percent Insiders 13.6 | Percent Institutions 24.55 |
Upturn AI SWOT
Biofrontera Inc
Company Overview
History and Background
Biofrontera Inc. was founded in 1997 and is a biopharmaceutical company specializing in the development and commercialization of dermatological products. It initially focused on research and development before transitioning to commercialization after receiving regulatory approvals.
Core Business Areas
- Prescription Drugs: Development and sales of prescription drugs for the treatment of skin diseases, primarily actinic keratosis.
- Dermatological Products: Marketing and distribution of dermatological products, including pharmaceuticals and cosmeceuticals.
Leadership and Structure
Biofrontera Inc. has a management team typically led by a CEO, CFO, and other key executives. Its organizational structure includes departments for research and development, sales and marketing, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Ameluzu00ae: Ameluzu00ae is a prescription drug used in combination with red light photodynamic therapy (PDT) for the treatment of actinic keratosis (AK). While exact market share is difficult to pinpoint, Ameluzu00ae competes with other AK treatments, including topical creams like imiquimod (Aldara), fluorouracil (Efudex), and diclofenac (Solaraze). Key competitors are companies marketing these alternative treatments.
Market Dynamics
Industry Overview
The dermatological market is characterized by increasing prevalence of skin diseases and growing demand for aesthetic treatments. It is driven by an aging population and increased awareness of skin health.
Positioning
Biofrontera Inc. is positioned as a specialty pharmaceutical company focused on innovative dermatological treatments, particularly in the area of photodynamic therapy. Its competitive advantage lies in its proprietary drug, Ameluzu00ae, and its associated PDT system.
Total Addressable Market (TAM)
The total addressable market for actinic keratosis treatment is estimated to be in the billions of dollars globally. Biofrontera Inc. is positioned to capture a portion of this TAM with its Ameluzu00ae product, particularly in the US and Europe.
Upturn SWOT Analysis
Strengths
- Proprietary drug (Ameluzu00ae)
- Established presence in the dermatology market
- Strong research and development capabilities
- FDA approved treatment
Weaknesses
- Limited product portfolio
- High dependence on Ameluzu00ae sales
- Relatively small market capitalization
- Fluctuations in Financial Performance
Opportunities
- Expansion into new geographical markets
- Development of new dermatological products
- Partnerships and collaborations with other companies
- Increasing awareness of actinic keratosis
Threats
- Competition from established pharmaceutical companies
- Generic erosion of Ameluzu00ae
- Changes in reimbursement policies
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- LEO Pharma (Private)
- Galderma (Private)
- Sun Pharmaceutical (SUNPHARMA.NS)
- Perrigo (PRGO)
Competitive Landscape
Biofrontera Inc. faces significant competition from larger pharmaceutical companies with broader product portfolios and greater resources. Its competitive advantage lies in its niche focus on photodynamic therapy and its proprietary drug, Ameluzu00ae.
Growth Trajectory and Initiatives
Historical Growth: The historical growth of Biofrontera Inc. has been characterized by fluctuations in revenue and profitability. Data cannot be provided because this is a Large Langauge Model.
Future Projections: Analyst data cannot be provided because this is a Large Langauge Model.
Recent Initiatives: Recent strategic initiatives include expanding sales and marketing efforts for Ameluzu00ae and pursuing regulatory approvals in new markets.
Summary
Biofrontera Inc. is a small biopharmaceutical company with a focus on dermatological products. The company's strength lies in its Ameluzu00ae product. However, Biofrontera faces challenges from larger competitors and needs to expand its product portfolio and improve its financial performance to achieve sustainable growth. Further development and expansion is needed to increase it's growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- Public filings
- Industry reports
- Analyst research
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source and methodology.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biofrontera Inc
Exchange NASDAQ | Headquaters Woburn, MA, United States | ||
IPO Launch date 2021-10-29 | CEO, President & Chairman Dr. Hermann Luebbert Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 92 | Website https://www.biofrontera-us.com |
Full time employees 92 | Website https://www.biofrontera-us.com | ||
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.